|
| |
Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules
|
Published: Jan 2012 | Pages: 87 | Pub ID: MM1326971814 |
|
|
|
 |
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Antipsychotics Market to 2017 - Introduction
2.1 GBI Report Guidance
3 Antipsychotics Market to 2017 - Global Market Overview
3.1 Introduction
3.2 Revenue Forecasts
3.2.1 Generic Share
3.3 Annual Cost of Treatment
3.4 Top Antipsychotics Drug Products
3.4.1 Seroquel (quetiapine)
3.4.2 Zyprexa (olanzapine)
3.4.3 Abilify (aripiprazole)
3.4.4 Risperdal (risperidone)
3.4.5 Geodon (ziprasidone)
3.5 Newer Antipsychotics
3.5.1 Fanapt (iloperidone)
3.5.2 Saphris / Sycrest (asenapine)
3.5.3 Invega Sustenna (paliperidone palmitate extended release injectable suspension)
3.5.4 Latuda (lurasidone Hcl)
4 Antipsychotics Market to 2017 - Geographical Landscape
4.1 Revenue Analysis by Geography
4.2 The US
4.2.1 Revenue
4.2.2 Annual Cost of Treatment
4.3 Top Five Countries of Europe
4.3.1 Revenue
4.3.2 Annual Cost of Treatment
4.4 Japan - Antipsychotics Market
4.4.1 Revenue
4.4.2 Annual Cost of Treatment
5 Antipsychotics Market to 2017 - Therapeutic Landscape
5.1 Bipolar Disorder - Antipsychotics Market
5.1.1 Introduction
5.1.2 Revenue
5.1.3 Annual Cost of Treatment
5.1.4 Treatment Usage Patterns
5.2 Drivers and Barriers to the Antipsychotics Market for Bipolar Disorder
5.2.1 Drivers for Bipolar Disorder Therapeutics Market
5.2.2 Barriers for Bipolar Disorder Therapeutics Market
5.3 Schizophrenia - Antipsychotics Market
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Annual Cost of Treatment
5.3.4 Treatment Usage Patterns
5.4 Drivers and Barriers to the Antipsychotics Market for Schizophrenia
5.4.1 Drivers for the Schizophrenia Therapeutics Market
5.4.2 Barriers for the Schizophrenia Therapeutics Market
6 Antipsychotics Market to 2017 - Product Pipeline Analysis
6.1 Introduction
6.1.1 Antipsychotics Market to 2017- Discovery Stage Molecules
6.1.2 Antipsychotics Market to 2017- Pre-clinical Stage Molecules
6.1.3 Antipsychotics Market to 2017- Phase I Stage Molecules
6.1.4 Antipsychotics Market to 2017- Phase II Stage Molecules
6.1.5 Antipsychotics Market to 2017- Phase III Stage Molecules
6.1.6 Antipsychotics Market to 2017- NDA Filed Molecules
6.1.7 NDA filed molecules
7 Antipsychotics Market to 2017 - Competitive Landscape
7.1 Market Share Analysis
7.1.1 AstraZeneca
7.1.2 Eli Lilly
7.1.3 Bristol-Myers Squibb (BMS)
7.1.4 Johnson & Johnson (J&J)
7.1.5 Pfizer
8 Antipsychotics Market to 2017 - M&A Landscape
8.1 M&A Deals (2007-2011)
8.1.1 M&A Deals by Region
8.1.2 M&A Deals by Value
8.1.3 M&A Deals by Year
8.1.4 Summary of M&A Deals (2009-2011)
8.2 Licensing Deals
8.2.1 Licensing Deals by Region
8.2.2 Licensing Deals by Year
8.2.3 Deal Summary (2010-2011)
8.3 Co-development Deals
8.3.1 Co-development Deals by Region
8.3.2 Co-development Deals by Year
8.3.3 Deal Summary (2010 - 2011)
9 Antipsychotics Market to 2017 - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Therapeutic Landscape
9.3.5 Geographical Landscape
9.3.6 Pipeline Analysis
9.3.7 Competitive Landscape
9.3.8 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources |
|
| By: GBI Research |
|
|
| |
|
|
|
US Office
India Office